Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624001358538
Ethics application status
Approved
Date submitted
15/10/2024
Date registered
13/11/2024
Date last updated
21/05/2025
Date data sharing statement initially provided
13/11/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
A first-in-human study of APG333 in healthy participants
Query!
Scientific title
A phase 1, randomized, blinded, placebo-controlled, first-in-human study of the safety, tolerability, and pharmacokinetics of single ascending doses of APG333 in healthy participants
Query!
Secondary ID [1]
313109
0
APG333-101
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Asthma
335356
0
Query!
Chronic obstructive pulmonary disease
335368
0
Query!
Condition category
Condition code
Respiratory
331943
331943
0
0
Query!
Chronic obstructive pulmonary disease
Query!
Respiratory
332159
332159
0
0
Query!
Asthma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
This study will evaluate single ascending doses (SAD) of APG333 administered subcutaneously (SC) in healthy participants. In each of 4 treatment cohorts (maximum), 8 participants will be randomized 6:2 to APG333 or placebo (up to 32 participants total).
Cohort 1 - APG333 Dose 125 milligram (mg) or placebo
Cohort 2 - APG333 Dose 250 mg or placebo
Cohort 3 - APG333 Dose 500 mg or placebo
Cohort 4 - APG333 Dose 1000 mg or placebo
The study will be conducted in Australia. The anticipated duration of the study is up to approximately 267 days, including screening and safety follow-up.
Query!
Intervention code [1]
329678
0
Treatment: Drugs
Query!
Comparator / control treatment
Placebo (0.9% sodium chloride) solution will be administered via SC injection.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
339548
0
Incidence of treatment-emergent adverse events (TEAEs) coded using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE), version 5.0
Query!
Assessment method [1]
339548
0
TEAEs (including those leading to discontinuation of study drug): collected via participant report and interviews performed by clinical site staff using non-leading questions, vital sign assessments, physical examinations and review of clinical safety laboratory test results and electrocardiogram (ECG) reports. The Investigator or designee will review each event (including injection site reactions) and assess its severity based on CTCAE version 5.0. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2: Moderate; minimal, local, or non-invasive intervention indicated; limiting age appropriate instrumental activities of daily living; Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting selfcare activities of daily living; Grade 4: Life-threatening consequences; urgent intervention indicated; Grade 5: Death related to adverse event (AE). Clinical safety laboratory findings- serum chemistry (including liver function tests, electrolytes, and kidney function tests), full blood count and coagulation tests; and urinalysis will be assessed. Vital signs will be measured on the arm opposite any intravenous (IV) canulae. Clinically significant laboratory findings and ECG findings will be reported as adverse events. Vital signs to be assessed include heart rate through stethoscope, blood pressure through digital sphygmomanometer, body temperature, and respiratory rate. Clinical research unit (CRU) standards will be used for determining normal ranges. Safety measures will be summarized independently using descriptive statistics.
Query!
Timepoint [1]
339548
0
Collection of AEs, physical examinations, and assessment of vital signs performed on Day 1: 0-hours (pre-dose), 4-, 8-, 24-, 48-, and 72-hours post-dose and on Days 8, 15, 22, 29, 57, 85, 113, 141, 169, 197, and 225 post-dose. ECGs performed on Day 1: 0-hours (pre-dose) and on Days 15, 22, 29, 85, 169, 197, and 225 post-dose. Clinical safety laboratory tests performed Day 1: 4-, 24- ,48-, 72-hours post-dose, and on Days 8, 22, 29, 57, 85, 113, 141, 169, 197, and 225 post-dose.
Query!
Secondary outcome [1]
440404
0
Assessment of pharmacokinetics (PK) parameters: Cmax, tmax, AUC0-last, AUC0-inf, Lambda-Z, t1/2, CL/F, Vz/F
Query!
Assessment method [1]
440404
0
Serum samples will be used to assess concentrations of APG333. Concentration-time data will be analysed by non-compartmental methods to assess PK outcomes including maximum observed serum concentration (Cmax), time to Cmax (tmax), area under the plasma concentration-time curve (AUC) from time 0 to the last quantifiable time point (AUC0–last), AUC from time 0 extrapolated to infinity (AUC0-inf), terminal elimination rate constant (Lambda-Z), terminal elimination half-life (t1/2), apparent clearance (CL/F), and apparent volume of distribution (Vz/F).
Query!
Timepoint [1]
440404
0
Day 1: 0-hours (pre-dose), 4-, 8-, 24-, 48-, and 72- hours post-dose and on Days 8, 15, 22, 29, 57, 85, 113, 141, 169, 197, and 225 post-dose
Query!
Secondary outcome [2]
440405
0
Number of participants with anti-drug antibodies (ADA)
Query!
Assessment method [2]
440405
0
Serum samples will be used to assess Anti-drug antibodies (ADA) outcomes. Analysis of samples for ADA will be performed using a validated ADA assay in a 3-tier format (screen, confirm, titer) and neutralizing antibody (NAb) assay in samples that have positive titers for ADA. Immunogenicity data summaries will include incidence of samples screened positive for ADA, incidence of samples confirmed positive for ADA, and summaries of ADA titers and NAb, as applicable.
Query!
Timepoint [2]
440405
0
Day 1: 0-hours (pre-dose) and on Days 15, 22, 29, 57, 85, 113, 141, 169, 197, and 225 post-dose
Query!
Eligibility
Key inclusion criteria
1. Healthy men and women, in the opinion of the Investigator and as determined by physical examination, laboratory screening tests, and medical history
2. 18 to 65 years of age with a body mass index of 18.0 to 32.0 kilogram per square meter (kg/m^2) (inclusive), weight less than (<) 120 kilogram (kg)
3. Willing to use a highly effective method of contraception through 30 days after end of study (EOS) or 5 half-lives after the last administration of study drug, whichever is longer
4. Willing to abstain from alcohol, tobacco, and illicit drug use for 48 hours prior to admission to the CRU (Day -1) and during the inpatient period.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
1. Evidence of clinically significant abnormalities or disease. History of any of the following:
a. Clinically significant opportunistic infection (eg, invasive candidiasis or pneumocystis pneumonia) within 5 years prior to Screening
b. Serious local infection (eg, cellulitis) or system infection (eg, septicemia) within 3 months prior to Screening
2. Known history of illicit drug abuse, harmful alcohol use (defined as an average of >10 standard drinks per week or at the Investigator’s discretion) or alcoholism, and/or excessive tobacco use (defined as >=5 cigarettes or e-cigarette equivalent [0.5 mL e cigarette fluid equivalent to 5 cigarettes] per day) within 2 years prior to Screening; positive screen for drugs of abuse (except tetrahydrocannabinol [THC]), or positive alcohol breath test at Screening or admission to the CRU (or at the Investigator’s discretion), and participants must abstain from cigarette smoking and vaping for the duration of their stay in the CRU. Participants may be rescreened for drugs of abuse or alcohol breath test at the Investigator’s discretion
3. History of severe allergic reactions or hypersensitivity (ie, anaphylaxis)
4. If female, nursing, lactating, pregnant, or plans to become pregnant within 30 days of EOS or 5 half-lives (whichever is longer) of study drug administration
5. Use of any prescription or nonprescription medication 7 days prior to dosing through CRU discharge Day 4 (exception: contraceptives, hormone replacement therapy, vitamins, over-the-counter [OTC] antihistamines, OTC topical steroids, or acetaminophen/paracetamol up to 2 gram (g) per day prior to dosing is permitted)
6. Use of any investigational drug therapy within 30 days or 5 half-lives (whichever is longer) prior to study drug dosing through 5 half-lives after the last dose of study drug
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation will occur via Interactive Response Technology (IRT) by an unblinded pharmacist.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block randomization.
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Safety
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Date of first participant enrolment
Anticipated
9/12/2024
Query!
Actual
18/11/2024
Query!
Date of last participant enrolment
Anticipated
3/04/2025
Query!
Actual
2/04/2025
Query!
Date of last data collection
Anticipated
12/11/2025
Query!
Actual
Query!
Sample size
Target
32
Query!
Accrual to date
Query!
Final
32
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Funding & Sponsors
Funding source category [1]
317553
0
Commercial sector/Industry
Query!
Name [1]
317553
0
Apogee Therapeutics, Inc.
Query!
Address [1]
317553
0
Query!
Country [1]
317553
0
United States of America
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Apogee Therapeutics, Inc.
Query!
Address
Query!
Country
United States of America
Query!
Secondary sponsor category [1]
319859
0
None
Query!
Name [1]
319859
0
Query!
Address [1]
319859
0
Query!
Country [1]
319859
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
316264
0
Bellberry Human Research Ethics Committee
Query!
Ethics committee address [1]
316264
0
123 Glen Osmond Rd, Eastwood SA 5063 (https://bellberry.com.au/)
Query!
Ethics committee country [1]
316264
0
Australia
Query!
Date submitted for ethics approval [1]
316264
0
02/10/2024
Query!
Approval date [1]
316264
0
08/11/2024
Query!
Ethics approval number [1]
316264
0
2024-10-1268
Query!
Summary
Brief summary
The main aim of the study is to test the safety, tolerability, pharmacokinetics, and immunogenicity of a single dose of APG333. The results of this study will help inform the dosing and frequency of dosing in patients with inflammatory diseases such as asthma and chronic obstructive pulmonary disease, which is the anticipated main therapeutic use for APG333.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
137330
0
Dr Michael Wong
Query!
Address
137330
0
Nucleus Network Brisbane, Level 5, 300C Herston Road, Herston, QLD 4006
Query!
Country
137330
0
Australia
Query!
Phone
137330
0
+61 07 3707 2720
Query!
Fax
137330
0
Query!
Email
137330
0
[email protected]
Query!
Contact person for public queries
Name
137331
0
Nucleus Network Brisbane
Query!
Address
137331
0
Nucleus Network Brisbane, Level 5, 300C Herston Road, Herston, QLD 4006
Query!
Country
137331
0
Australia
Query!
Phone
137331
0
+61 1800 243 733
Query!
Fax
137331
0
Query!
Email
137331
0
[email protected]
Query!
Contact person for scientific queries
Name
137332
0
Nucleus Network Brisbane
Query!
Address
137332
0
Nucleus Network Brisbane, Level 5, 300C Herston Road, Herston, QLD 4006
Query!
Country
137332
0
Australia
Query!
Phone
137332
0
+61 1800 243 733
Query!
Fax
137332
0
Query!
Email
137332
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
No
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF